MedTrace Logo

Use Of Fragmin In Hemodialysis

NCT01879618 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2017-03-10

Study results available
· View outcomes & findings →

Summary

The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.

Conditions

  • Chronic Renal Failure

Interventions

DRUG

Fragmin

variable dosing regimen

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01879618 on ClinicalTrials.gov